Patient characteristics and main events
| . | ICD cohort (n = 730) . | EBMT cohort (n = 384) . |
|---|---|---|
| Year of diagnosis | 2008 (2004-2010) | 2011 (2008-2013) |
| Age at diagnosis, years | 64.0 (58.8-67.8) | 57.3 (51.0-61.9) |
| Sex | ||
| Male | 508 (69.6) | 266 (69.3) |
| Female | 222 (30.4) | 118 (30.7) |
| FAB subsets | ||
| CMML-MD | 348 (47.7) | 173 (45) |
| CMML-MP | 382 (52.3) | 211 (55) |
| WHO category* | ||
| CMML-1 | 582 (79.7) | 238 (62) |
| CMML-2 | 148 (20.3) | 146 (38) |
| Hemoglobin level | ||
| ≥10 gr/dl | 472 (64.7) | 235 (61.2) |
| <10 gr/dl | 258 (35.3) | 149 (38.8) |
| Cytogenetic risk† | ||
| Low | 498 (68.2) | 264 (68.7) |
| Intermediate | 113 (15.5) | 46 (12.0) |
| High | 119 (16.3) | 74 (19.3) |
| CPSS risk‡ | ||
| Low | 159 (21.8) | 61 (15.9) |
| Intermediate-1 | 227 (31.1) | 116 (30.2) |
| Intermediate-2 | 286 (39.2) | 162 (42.2) |
| High | 58 (7.9) | 45 (11.7) |
| Follow-up duration from diagnosis, months (median, 95% CI) | 51.06 (47.34-56.77) | 78.03 (67.61-84.07) |
| Underwent allo-HCT | 98 (13.4) | 384 (100) |
| Transformation to AML before allo-HCT | 33 (33.7)§ | 78 (20.3) |
| . | ICD cohort (n = 730) . | EBMT cohort (n = 384) . |
|---|---|---|
| Year of diagnosis | 2008 (2004-2010) | 2011 (2008-2013) |
| Age at diagnosis, years | 64.0 (58.8-67.8) | 57.3 (51.0-61.9) |
| Sex | ||
| Male | 508 (69.6) | 266 (69.3) |
| Female | 222 (30.4) | 118 (30.7) |
| FAB subsets | ||
| CMML-MD | 348 (47.7) | 173 (45) |
| CMML-MP | 382 (52.3) | 211 (55) |
| WHO category* | ||
| CMML-1 | 582 (79.7) | 238 (62) |
| CMML-2 | 148 (20.3) | 146 (38) |
| Hemoglobin level | ||
| ≥10 gr/dl | 472 (64.7) | 235 (61.2) |
| <10 gr/dl | 258 (35.3) | 149 (38.8) |
| Cytogenetic risk† | ||
| Low | 498 (68.2) | 264 (68.7) |
| Intermediate | 113 (15.5) | 46 (12.0) |
| High | 119 (16.3) | 74 (19.3) |
| CPSS risk‡ | ||
| Low | 159 (21.8) | 61 (15.9) |
| Intermediate-1 | 227 (31.1) | 116 (30.2) |
| Intermediate-2 | 286 (39.2) | 162 (42.2) |
| High | 58 (7.9) | 45 (11.7) |
| Follow-up duration from diagnosis, months (median, 95% CI) | 51.06 (47.34-56.77) | 78.03 (67.61-84.07) |
| Underwent allo-HCT | 98 (13.4) | 384 (100) |
| Transformation to AML before allo-HCT | 33 (33.7)§ | 78 (20.3) |